TY - JOUR
T1 - Platelet-Rich Plasma and Marrow Venting May Serve as Cost-Effective Augmentation Techniques for Isolated Meniscal Repair
T2 - A Decision-Analytical Markov Model–Based Analysis
AU - Oeding, Jacob F.
AU - Berlinberg, Elyse J.
AU - Lu, Yining
AU - Marigi, Erick M.
AU - Okoroha, Kelechi R.
AU - Camp, Christopher L.
AU - Barlow, Jonathan D.
AU - Krych, Aaron J.
N1 - Funding Information:
The authors report the following potential conflicts of interest or sources of funding: E.J.B. owns stocks or stock options in Amgen and Pfizer, outside the submitted work. K.R.O. is a paid consultant for Arthrex and Smith & Nephew, outside the submitted work. C.L.C. receives intellectual property (IP) royalties from Arthrex and receives research support from Major League Baseball, outside the submitted work. J.D.B. receives IP royalties from Stryker and is a paid consultant for Stryker, outside the submitted work. A.J.K. receives research support from Aesculap/B.Braun and Arthrex; is on the editorial or governing board of American Journal of Sports Medicine; receives IP royalties from Arthrex; is a paid consultant for Arthrex; and is a board or committee member of International Cartilage Repair Society and International Society of Arthroscopy, Knee Surgery and Orthopaedic Sports Medicine, outside the submitted work. Full ICMJE author disclosure forms are available for this article online, as supplementary material .
Funding Information:
The authors report the following potential conflicts of interest or sources of funding: E.J.B. owns stocks or stock options in Amgen and Pfizer, outside the submitted work. K.R.O. is a paid consultant for Arthrex and Smith & Nephew, outside the submitted work. C.L.C. receives intellectual property (IP) royalties from Arthrex and receives research support from Major League Baseball, outside the submitted work. J.D.B. receives IP royalties from Stryker and is a paid consultant for Stryker, outside the submitted work. A.J.K. receives research support from Aesculap/B.Braun and Arthrex; is on the editorial or governing board of American Journal of Sports Medicine; receives IP royalties from Arthrex; is a paid consultant for Arthrex; and is a board or committee member of International Cartilage Repair Society and International Society of Arthroscopy, Knee Surgery and Orthopaedic Sports Medicine, outside the submitted work. Full ICMJE author disclosure forms are available for this article online, as.
Publisher Copyright:
© 2023
PY - 2023
Y1 - 2023
N2 - Purpose: To evaluate the cost-effectiveness of 3 isolated meniscal repair (IMR) treatment strategies: platelet-rich plasma (PRP)–augmented IMR, IMR with a marrow venting procedure (MVP), and IMR without biological augmentation. Methods: A Markov model was developed to evaluate the baseline case: a young adult patient meeting the indications for IMR. Health utility values, failure rates, and transition probabilities were derived from the published literature. Costs were determined based on the typical patient undergoing IMR at an outpatient surgery center. Outcome measures included costs, quality-adjusted life-years (QALYs), and the incremental cost-effectiveness ratio (ICER). Results: Total costs of IMR with an MVP were $8,250; PRP-augmented IMR, $12,031; and IMR without PRP or an MVP, $13,326. PRP-augmented IMR resulted in an additional 2.16 QALYs, whereas IMR with an MVP produced slightly fewer QALYs, at 2.13. Non-augmented repair produced a modeled gain of 2.02 QALYs. The ICER comparing PRP-augmented IMR versus MVP-augmented IMR was $161,742/QALY, which fell well above the $50,000 willingness-to-pay threshold. Conclusions: IMR with biological augmentation (MVP or PRP) resulted in a higher number of QALYs and lower costs than non-augmented IMR, suggesting that biological augmentation is cost-effective. Total costs of IMR with an MVP were significantly lower than those of PRP-augmented IMR, whereas the number of additional QALYs produced by PRP-augmented IMR was only slightly higher than that produced by IMR with an MVP. As a result, neither treatment dominated over the other. However, because the ICER of PRP-augmented IMR fell well above the $50,000 willingness-to-pay threshold, IMR with an MVP was determined to be the overall cost-effective treatment strategy in the setting of young adult patients with isolated meniscal tears. Level of Evidence: Level III, economic and decision analysis.
AB - Purpose: To evaluate the cost-effectiveness of 3 isolated meniscal repair (IMR) treatment strategies: platelet-rich plasma (PRP)–augmented IMR, IMR with a marrow venting procedure (MVP), and IMR without biological augmentation. Methods: A Markov model was developed to evaluate the baseline case: a young adult patient meeting the indications for IMR. Health utility values, failure rates, and transition probabilities were derived from the published literature. Costs were determined based on the typical patient undergoing IMR at an outpatient surgery center. Outcome measures included costs, quality-adjusted life-years (QALYs), and the incremental cost-effectiveness ratio (ICER). Results: Total costs of IMR with an MVP were $8,250; PRP-augmented IMR, $12,031; and IMR without PRP or an MVP, $13,326. PRP-augmented IMR resulted in an additional 2.16 QALYs, whereas IMR with an MVP produced slightly fewer QALYs, at 2.13. Non-augmented repair produced a modeled gain of 2.02 QALYs. The ICER comparing PRP-augmented IMR versus MVP-augmented IMR was $161,742/QALY, which fell well above the $50,000 willingness-to-pay threshold. Conclusions: IMR with biological augmentation (MVP or PRP) resulted in a higher number of QALYs and lower costs than non-augmented IMR, suggesting that biological augmentation is cost-effective. Total costs of IMR with an MVP were significantly lower than those of PRP-augmented IMR, whereas the number of additional QALYs produced by PRP-augmented IMR was only slightly higher than that produced by IMR with an MVP. As a result, neither treatment dominated over the other. However, because the ICER of PRP-augmented IMR fell well above the $50,000 willingness-to-pay threshold, IMR with an MVP was determined to be the overall cost-effective treatment strategy in the setting of young adult patients with isolated meniscal tears. Level of Evidence: Level III, economic and decision analysis.
UR - http://www.scopus.com/inward/record.url?scp=85151521997&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85151521997&partnerID=8YFLogxK
U2 - 10.1016/j.arthro.2023.02.018
DO - 10.1016/j.arthro.2023.02.018
M3 - Article
C2 - 36868533
AN - SCOPUS:85151521997
SN - 0749-8063
JO - Arthroscopy - Journal of Arthroscopic and Related Surgery
JF - Arthroscopy - Journal of Arthroscopic and Related Surgery
ER -